Welcome to our dedicated page for Globus Med news (Ticker: GMED), a resource for investors and traders seeking the latest updates and insights on Globus Med stock.
Globus Medical Inc (NYSE: GMED) drives innovation in musculoskeletal solutions and surgical robotics, delivering cutting-edge technologies for spinal and orthopedic procedures. This dedicated news hub provides investors and medical professionals with essential updates on the company's advancements in medical device innovation.
Key Resources: Access official press releases, financial announcements, and strategic partnership updates in one centralized location. Track developments in robotic-assisted surgery platforms, regulatory milestones for spinal implants, and clinical trial progressions shaping modern surgical care.
Content Focus: Our curated collection includes earnings reports, product launch details, FDA clearance announcements, and technology partnership disclosures. Stay informed about GMED's expanding portfolio of enabling technologies designed to enhance surgical precision and patient outcomes.
Stay Updated: Bookmark this page for real-time access to verified information about Globus Medical's market-moving developments. Regularly refreshed content ensures you maintain awareness of critical innovations in the evolving medical devices sector.
Globus Medical (NYSE:GMED), a leading musculoskeletal technology company, has scheduled its first quarter 2025 financial results announcement for Thursday, May 8, 2025, after market close. The company will host a conference call at 4:30 p.m. Eastern Time to discuss the Q1 performance ending March 31, 2025.
Investors can access the earnings release through the company's investor relations website at www.investors.globusmedical.com. The conference call will be available via:
- Webcast: Through the Investors page on Globus Medical's website
- Telephone: Participants must pre-register using the provided link to receive dial-in details, passcode, and registrant ID
An audio archive of the call will be made available on the company's investor website following the event.
Globus Medical (NYSE: GMED) has completed its acquisition of Nevro Corp., a medical device company specializing in chronic pain treatment solutions. The strategic acquisition expands Globus Medical's presence in the musculoskeletal market, unlocking a $2.5 billion market opportunity in the neuromodulation space.
The deal aims to accelerate market penetration of Nevro's high-frequency technology for chronic pain treatment. Nevro's common stock has ceased trading on the NYSE as of April 3, 2025. Globus Medical plans to discuss the acquisition's benefits during its first quarter earnings conference in May.
Morgan Stanley & Co. and BofA Securities, Inc. served as financial advisors to Globus Medical and Nevro Corp., respectively.
Globus Medical (NYSE: GMED) has announced two significant product launches in its anterior spine portfolio: the COHERE™ ALIF Spacer and Modulus™ ALIF Blades.
The COHERE ALIF Spacer is the first Porous PEEK™ interbody spacer for anterior lumbar interbody fusion surgery, featuring proprietary porous surface technology for bone in-growth while maintaining imaging and mechanical properties. The technology combines PEEK's stiffness and radiolucency with osseointegration potential.
The Modulus ALIF Blades extend the Modulus ALIF Spacer portfolio by offering different fixation options and improved procedural efficiency through immediate anchoring blade fixation following interbody spacer placement. This innovation reduces the number of surgical steps and instruments needed, allowing for a more minimally invasive approach.
Globus Medical (NYSE: GMED) announced its participation in the 2025 American Academy of Orthopedic Surgeons (AAOS) Annual Meeting in San Diego from March 10-14, 2025. The company will showcase its comprehensive product portfolio at booth #2517, highlighting their latest innovation, the ExcelsiusFlex™ surgical robotic navigation system for Total Knee Arthroplasty (TKA).
The ExcelsiusFlex™ system combines accuracy, procedural flexibility, and surgeon-centric design, allowing customization of workflow. The company will also feature the PRECICE™ Intramedullary Limb Lengthening Portfolio, DuraPro™ Oscillating System, and Harvest™ SmartPrep™ 3 autologous biologic centrifuge platform.
Globus Medical will host a reception on March 12, 2025, from 5:30pm to 8:30pm at the San Diego Wine & Culinary Center, and a booth tour for analysts and investors from 1:00pm to 1:45pm the same day.
Globus Medical (NYSE: GMED), a leading musculoskeletal technology company, has announced its participation in the Canaccord Genuity 2025 Musculoskeletal Conference in San Diego. The company's management team is scheduled to deliver a presentation on Monday, March 10, 2025, at 4:30 PM Pacific Time.
Investors and interested parties can access both the live presentation and archived webcast through the company's investor relations website under the 'News & Events' and 'Events & Webcasts' sections at investors.globusmedical.com.
Nevro Corp. (NYSE: NVRO) reported its Q4 and full-year 2024 financial results, highlighting a pending acquisition by Globus Medical for $250 million ($5.85 per share) expected to close in Q2 2025. The company's Q4 2024 worldwide revenue decreased 9.1% to $105.5 million, with U.S. revenue declining 9.9% to $91.4 million.
Key Q4 metrics include: gross profit of $65.9 million (62.5% margin), net loss from operations of $51.4 million, and adjusted EBITDA of negative $5.2 million. For full-year 2024, worldwide revenue decreased 3.9% to $408.5 million, with gross profit at $269.5 million (66.0% margin).
Notable developments include the launch of HFX iQ™ with HFX AdaptivAI™ platform in November 2024 and its European expansion in January 2025. The company's cash position strengthened to $292.5 million as of December 31, 2024.
Globus Medical (NYSE: GMED) reported strong financial results for Q4 and full year 2024. Q4 worldwide net sales reached $657.3 million, up 6.6% year-over-year, with GAAP net income of $26.5 million and EPS of $0.19. Non-GAAP diluted EPS was $0.84, and adjusted EBITDA was $196.9 million.
Full year 2024 sales totaled $2,519.4 million, a 60.6% increase, with GAAP net income of $103.0 million and EPS of $0.75. Non-GAAP diluted EPS was $3.04, and adjusted EBITDA reached $735.0 million. The company generated operating cash flow of $520.6 million and non-GAAP free cash flow of $405.2 million.
For 2025, GMED projects standalone revenue of $2.66-2.69 billion with non-GAAP EPS of $3.40-3.50. Post-Nevro acquisition, expected in late Q2 2025, guidance increases to $2.80-2.90 billion in sales with non-GAAP EPS of $3.10-3.40.
Globus Medical (NYSE: GMED) has announced the acquisition of Nevro Corp. (NYSE: NVRO) in an all-cash transaction valued at approximately $250 million. Under the agreement, Globus Medical will acquire all Nevro shares for $5.85 per share, representing a 27% premium to the 90-day VWAP.
The transaction, expected to close in late Q2 2025, aims to expand Globus Medical's presence in neuromodulation and pain management technologies. The company anticipates 2025 net sales of $2.80-2.90 billion post-acquisition, with the deal expected to be earnings accretive in the second year of operation.
For 2024, Globus Medical reported preliminary net sales of $2.52 billion, a 60.6% increase year-over-year, while Nevro's preliminary worldwide revenue was $408-409 million. The acquisition has received unanimous approval from both companies' boards of directors and is subject to Nevro shareholder and regulatory approvals.
Globus Medical (NYSE:GMED) has scheduled its fourth quarter and full-year 2024 financial results announcement for Thursday, February 20, 2025, after market close. The company will host a conference call with the investment community at 4:30 p.m. Eastern Time on the same day.
Investors can access the conference call through a live webcast on the company's investor relations website. For telephone participation, advance registration is required through a provided link, after which participants will receive dial-in details and unique access credentials. An audio archive of the call will be made available on the company's investor website following the event.
Globus Medical (NYSE: GMED) reported preliminary Q4 2024 sales of $657.0 million, up 6.6% year-over-year, and full-year 2024 sales of $2.52 billion, representing a 60.6% increase from 2023. The company, following its NuVasive merger, achieved strong sales growth, record new product launches, and highest Enabling Technology placements while accelerating merger synergies.
Looking ahead, GMED provided 2025 guidance with revenue projected between $2.66 billion to $2.69 billion and non-GAAP EPS guidance of $3.40 to $3.50. The company plans to announce detailed Q4 and full-year 2024 results on February 20, 2025.
